Catalyst Pharmaceuticals Inc (FRA:CN2) Stock Price, Trades & News

Catalyst Pharmaceuticals Inc is a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living with rare and difficult to treat diseases. The Company sells three commercial stage drug products, FIRDAPSE (amifampridine), AGAMREE (vamorolone), and FYCOMPA (perampanel). The Company is currently seeking to further expand its product portfolio, with a focus on acquiring the rights to immediately and near-term accretive assets to treat rare (orphan) diseases across therapeutic areas, including clinical-stage opportunities with established proof of concept.

Financial Strength

8/10

Name	Current	Vs Industry	Vs History
Cash-To-Debt	281.93
Equity-to-Asset	0.88
Debt-to-EBITDA	0.01
Interest Coverage	N/A	N/A	N/A
Piotroski F-Score	5/9	0 1 2 3 4 5 6 7 8 9
Altman Z-Score	20	Distress Grey Safe
Beneish M-Score	-1.84	Manipulator Not Manipulator
WACC vs ROIC		WACC ROIC

Growth Rank

10/10

	Name	Current	Vs Industry		Vs History
	3-Year Revenue Growth Rate	34
	3-Year EBITDA Growth Rate	35.9
	3-Year EPS without NRI Growth Rate	38.7
	3-Year FCF Growth Rate	16.3
	3-Year Book Growth Rate	39.7
	Future 3-5Y Total Revenue Growth Rate Estimate	10.65

Momentum Rank

9/10

	Name	Current	Vs Industry		Vs History
	5-Day RSI	59.75
	9-Day RSI	57.83
	14-Day RSI	59.07
	3-1 Month Momentum %	22.48
	6-1 Month Momentum %	36.71
	12-1 Month Momentum %	46.7

Liquidity Ratio

	Name	Current	Vs Industry		Vs History
	Current Ratio	7.1
	Quick Ratio	6.84
	Cash Ratio	5.71
	Days Inventory	120.67
	Days Sales Outstanding	61.25
	Days Payable	38.47

Dividend & Buy Back

	Name	Current	Vs Industry		Vs History
	3-Year Average Share Buyback Ratio	-5.2
	Shareholder Yield %	0.39

Profitability Rank

8/10

	Name	Current	Vs Industry		Vs History
	Gross Margin %	85.96
	Operating Margin %	44.83
	Net Margin %	37.08
	EBITDA Margin %	51.23
	FCF Margin %	34.95
	OCF Margin %	34.95
	ROE %	24.39
	ROA %	21.35
	ROIC %	81.33
	3-Year ROIIC %	57.11
	ROC (Joel Greenblatt) %	970.63
	ROCE %	29.4
	Years of Profitability over Past 10-Year	7
	Moat Score	6
	Tariff Resilience Score	7

GF Value Rank

5/10

	Name	Current	Vs Industry		Vs History
	PE Ratio	18.1
	Forward PE Ratio	16.11
	PE Ratio without NRI	15.66
	Shiller PE Ratio	53.75
	Price-to-Owner-Earnings	25.64
	PEG Ratio	0.35
	PS Ratio	6.71
	PB Ratio	3.8
	Price-to-Tangible-Book	4.32
	Price-to-Free-Cash-Flow	19.26
	Price-to-Operating-Cash-Flow	19.25
	EV-to-EBIT	11.59
	EV-to-Forward-EBIT	11.07
	EV-to-EBITDA	10.14
	EV-to-Revenue	5.2
	EV-to-Forward-Revenue	4.91
	EV-to-FCF	14.9
	Price-to-GF-Value	1.27
	Price-to-Projected-FCF	1.49
	Price-to-Peter-Lynch-Fair-Value	0.63
	Price-to-Graham-Number	1.73
	Price-to-Net-Current-Asset-Value	4.78
	Price-to-Net-Cash	6.2
	Earnings Yield (Greenblatt) %	8.63
	FCF Yield %	5.4
	Forward Rate of Return (Yacktman) %	23.71

Financials (Next Earnings Date:2026-08-06 Est.)

Annual Quarterly TTM

FRA:CN2's 30-Y Financials

AAPL

Income Statement Breakdown FY

Annual Quarterly

Not Enough Data

AAPL

Balance Sheet Breakdown

Annual Quarterly

Not Enough Data

AAPL

Cashflow Statement Breakdown

Annual Quarterly

Not Enough Data

Operating Revenue by Business Segment

Operating Revenue by Geographic Region

Historical Operating Revenue by Business Segment

Value % YoY

Historical Operating Revenue by Geographic Region

Value % YoY

See Details

5-Step DuPont Analysis as of

Annual Quarterly

Not Enough Data

Guru Trades

See Details

Insider Trades

See Details

Peter Lynch Chart

Y-axis scale:

Log Linear

Interactive Chart

Performance

Dividend

Log

Bar

Annualized Return %

Symbol	1 Week	1 Month	3 Months	6 Months	YTD	1 Year	3 Years	5 Years	10 Years

Total Annual Return %

Symbol	2026	2025	2024	2023	2022	2021	2020	2019	2018	2017

Catalyst Pharmaceuticals Inc Executives

Details

GF Value™: €21.47

FRA:CN2

Valuation Chart

Year:

Warning Signs

Warning! GuruFocus detected 1 Severe warning sign with CN2. Try a 7-Day Free Trial to check it out.

Analyst Estimate

Annual Quarterly

Key Statistics

	Name	Value
	Revenue (TTM) (Mil €)	513.054
	EPS (TTM) (€)	1.495
	Beta	0.9628
	3-Year Sharpe Ratio	0.96
	3-Year Sortino Ratio	1.73
	Volatility %	24.44
	14-Day RSI	59.07
	14-Day ATR (€)	0.14887
	20-Day SMA (€)	27.16
	12-1 Month Momentum %	46.7
	52-Week Range (€)	16.15 - 27.4
	Shares Outstanding (Mil)	122.42

Piotroski F-Score Details

Year:

	Component	Result
	Piotroski F-Score	5
	Positive ROA
	Positive CFROA
	Higher ROA yoy
	CFROA > ROA
	Lower Leverage yoy
	Higher Current Ratio yoy
	Less Shares Outstanding yoy
	Higher Gross Margin yoy
	Higher Asset Turnover yoy

Catalyst Pharmaceuticals Inc Filings

10-K10-QForm 4Others

	Filing Date	Document Date	Form
No Filing Data

Catalyst Pharmaceuticals Inc Stock Events

Financials Calendars

Event	Date	Price (€)
Third quarter earnings conference call for 2026	2026-11-06 08:30	In 108 days
Third quarter earnings results for 2026	2026-11-05	In 106 days
Second quarter earnings conference call for 2026	2026-08-07 08:30	In 17 days
Second quarter earnings results for 2026	2026-08-06	In 15 days
General meeting for 2025	2026-07-22 09:00	In 1 day
First quarter earnings results for 2026	2026-05-11	26.40 (+0.76%)
Barclays 28th Annual Global Healthcare Conference	2026-03-10 15:30	20.31 (+0.00%)
Fourth quarter earnings conference call for 2025	2026-02-26 08:30	20.19 (+0.00%)
Annual report for 2025	2026-02-25	20.17 (+0.00%)
Fourth quarter earnings results for 2025	2026-02-25	20.17 (+0.00%)

Show

Entries

Catalyst Pharmaceuticals Inc Frequently Asked Questions

What is Catalyst Pharmaceuticals Inc(FRA:CN2)'s stock price today?

The current price of FRA:CN2 is €27.30. The 52 week high of FRA:CN2 is €27.40 and 52 week low is €16.15.

When is next earnings date of Catalyst Pharmaceuticals Inc(FRA:CN2)?

The next earnings date of Catalyst Pharmaceuticals Inc(FRA:CN2) is 2026-08-06 Est..

Does Catalyst Pharmaceuticals Inc(FRA:CN2) pay dividends? If so, how much?

Catalyst Pharmaceuticals Inc(FRA:CN2) does not pay dividend.

Press Release

	Subject	Date
	Solaris Energy Infrastructure Set to Join S&P SmallCap 600	2026-07-09
	Are NUVL, CPRX, TMHC Obtaining Fair Deals for their Shareholders?	2026-06-25
	Catalyst Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Catalyst Pharmaceuticals, Inc. - CPRX	2026-06-24
	Are KALV, GBTG, MDV, CPRX Obtaining Fair Deals for their Shareholders?	2026-05-19
	Are CPRX, UNF, RMAX, ACR Obtaining Fair Deals for their Shareholders?	2026-05-12
	Thinking about buying stock in Praxis Precision Medicines, Safety Shot, Catalyst Pharmaceuticals, Adicet Bio, or Exscientia?	2024-03-21
	Thinking about buying stock in Analog Devices,Catalyst Pharmaceuticals, QuickLogic, Synopsys, or Pagaya Technologies?	2024-03-19
	Thinking about buying stock in JetBlue Airways, Hecla Mining, Catalyst Pharmaceuticals, Energy Transfer, or Ford?	2023-05-15
	Thinking about buying stock in AbbVie, Aurora Cannabis, Catalyst Pharmaceuticals, Fibrocell Science, or MER Telemanagement Solutions?	2019-09-13

10/Page

Articles on Catalyst Pharmaceuticals Inc

No articles.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.